J. Yaxley

The supportive care needs of men with prostate cancer (2000)

The diagnosis and subsequent treatment of prostate cancer is followed by a range of significant disease specific and iatrogenic sequelae. However, the supportive care needs of men with prostate cancer are not well described in the literature. The present study assesses the supportive care needs of men with prostate cancer who are members of prostate cancer self‐help groups in Queensland, Australia. In all, 206 men aged between 48 and 85 years (mean=68) completed the Supportive Care Needs Survey (SCNS) (62% response). The SCNS is a validated measure assessing perceived need in the domains of psychological needs, health system and information needs, physical and daily living needs, patient care and support, and sexuality. Items assessing need for access to services and resources were also included.

Making decisions about treatment for localized prostate cancer.

Objective To describe the decision‐making processes used by men diagnosed with localized prostate cancer who were considering treatment.

Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.

To investigate the effects of different management strategies for non‐localized prostate cancer on mens quality of life and cognitive functioning.

Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years.

To evaluate the long‐term outcomes of high‐dose‐rate (HDR) brachytherapy for patients with intermediate‐ and high‐risk prostate cancer.

Inactive free : total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men

Objective To measure free : total prostate specific antigen (PSA) ratios in ejaculate from men with suspected and known prostate cancer, and in young control men, to determine if this ratio might be useful in discriminating benign from malignant prostatic conditions.

Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review

Abstract Background: Analgesic nephropathy (AN) is chronic renal impairment as a direct consequence of chronic heavy analgesia ingestion. An association between non-steroidal anti-inflammatory agents and chronic kidney disease (CKD) has long been suspected. Despite ample observational data obtained in recent decades the relationship remains uncertain. This systematic review intends to summarize the available literature and to define the role of non-steroidal anti-inflammatories in the natural history of AN. Methods: We conducted a systematic literature search for articles describing the association between non-steroidal anti-inflammatory abuse and renal insufficiency. No restriction was placed on publication date, but papers were limited to English language, observational design, and human studies. Results: Nine articles met our inclusion criteria and were discussed in this review. This includes 5 cohort studies and 4 case–control trials, with a combined population of 12,418 study subjects and 23,877 controls. Eight of the nine reports failed to identify any increased risk of chronic renal impairment with heavy non-steroidal anti-inflammatory consumption. Study methods were heterogeneous and the overall quality of data was relatively poor. Conclusion: A relationship between non-steroidal anti-inflammatory medicines and the development of CKD has never been proven. Based on the available scientific evidence non-steroidal anti-inflammatory agents do not appear to be implicated in the pathogenesis of AN.

Altered Cognitive Function in Men Treated for Prostate Cancer with LHRH Analogues and Cyproterone Acetate: A Randomised Controlled Trial

Objective  To report the first systematic investigation of the cognitive effects of luteinizing hormone‐releasing hormone (LHRH) analogues in male patients, as LHRH analogues have been associated with memory impairments in women using these drugs for gynaecological conditions.

True false negative of MRI scans for prostate cancer screening. How often does MRI miss

Introduction: Ureteric stent placement is oft en associated with morbidity ranging from mild generalised discomfort to signifi cant storage urinary symptoms and loin pain. Our unit identifi ed a high rate of patients re-presenting with side eff ects aft er placement of a ureteric stent. Whilst most re-presentations for common side eff ects only require conservative management they can lead to potentially unnecessary emergency department (ED) consultations, additional investigations and out-of-hours admissions for symptomatic control. All these events result in potentially avoidable increased healthcare costs. Objectives: Prospective single institution audit to assess whether the provision of a written information pamphlet detailing common expected side-eff ects of ureteric stents at the time of discharge in newly stented patients would reduce the rate of re-presentation to hospital related to benign side eff ects and therefore reduce the costs associated with unnecessary emergency room attendances, investigations and occasional hospital admission. Methods: A local stent register was used to identify patients who had ureteric stents inserted 1 year preand post-introduction of the stent information pamphlet. Th e stent information pamphlet was introduced on 5th July 2013. A total of 194 patients had a ureteric stent(s) inserted from 5th July 2012 to 4th July 2013 (Group 1) and a total of 226 patients had a ureteric stent(s) inserted from 5th July 2013 to 5th July 2014 (Group 2). All patients who had ureteric stents inserted during this period were included in the audit, regardless of the initial indication for ureteric stent insertion. Results: Th ere was a 50/194 (25%) and 34/226 (15%) rate of re-presentations preand postimplementation of the stent information pamphlet respectively. Th is refl ected a clinically and statistically signifi cant 10% decrease in the percentage of re-presentations ( P = 0.006) with patients in the pre-implementation group also showing a 1.96 times increased likelihood of re-presenting to hospital (OR = 1.961, 96%CI: 1.206–3.189). Th ere was an average cost saving of

Prostate needle biopsy is predictive of neurovascular bundle involvement in radical prostatectomy

899 per ED re-presentation and an additional average cost saving of

A Randomised Open and Robotic Prostatectomy: Trial Methodology

1936 for each re-presentation resulting in an inpatient stay. Th e reduction in ED re-presentations also released an average of 5.2 h of ED consultation time per patient as well as 23 h of inpatient hospital bed space availability. Conclusions: Ureteric stent information pamphlets resulted in a 10% reduction in hospital re-presentation rates leading to substantial cost savings for the hospital and healthcare system and should therefore be routinely used.